Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
CONSULTANT IN MEDICAL ONCOLOGY with an interest in Gynaecological Malignancy, cancer of unknown primary and Acute Oncology at Central Manchester University Hospitals. 1. Background Information This is a new post, supported by the Greater Manchester and Cheshire Cancer Network and The Christie NHS Trust. Candidates must by law be on the General Medical Council Specialist Register in Medical Oncology or they must provide evidence that they will be on the register by the time that they take up this appointment. The purpose of the new post is to strengthen the Medical Oncology service for patients living in the Greater Manchester and Cheshire Network, with particular emphasis on Gynaecological Malignancy and cancer of unknown primary. In addition this post will provide Acute Oncology input at Central Manchester University Hospitals. The successful applicant would become an active member of the Christie Lung and Gynaecological Malignancy group, consisting of surgeons, clinical oncologists and medical oncologists, pathologists, radiologists, nursing and allied health professionals. The new consultant would be based at The Christie, but would also work closely with the Gynaecological Malignancy team at Central Manchester University Hospitals in terms of providing advice on systemic anticancer therapy and development pathways and treatment plans. The successful applicant would be expected to develop/enhance systemic anti-cancer therapy clinical trials activity at Central Manchester University Hospitals and The Christie Hospital. 2. The Christie NHS Foundation Trust The Christie Hospital and Holt Radium Institute was founded in 1932 and has grown to be the largest Cancer Hospital in the UK and one of the largest Cancer Centres in Europe covering a large population in North West England. The Trust is a designated teaching hospital of the University of Manchester and is the focal point of the Regional Cancer Network. All cancer related specialties are fully operational and more than 13,000 new patients with cancer are seen each year. It is a major Cancer research centre and combined with University of Manchester, the Paterson Institute for Cancer Research and Cancer Research UK comprises the Manchester Cancer Research Centre. The Trust is composed of three clinical management divisions Networked Services Division – Director Professor Nick Slevin – includes the Departments of 1 Medical Oncology, Clinical Oncology, Haematology, Palliative Care, Paediatric and Adolescent Oncology Cancer Centre Services – Director – Miss Sarah O’Dwyer - Surgery, Anaesthetics, HDU, Endocrinology and Haematology Clinical Support Services – Director Dr Jeremy Lawrence - Radiology, Pathology, Pharmacy, Supportive Care Other support services are provided by the Corporate services Division including Finance, Nursing & Operations and Estates & Facilities. Both the Departments of Medical Oncology (Director: Dr Andrew Wardley) and Clinical Oncology (Director: Dr John Logue), have international reputations for their clinical work. Consultants are site specialised and common treatment policies are developed through the multi-disciplinary Disease Groups (DGs). Links to the cancer units are maintained through a number of peripheral and outreach clinics across the Greater Manchester and Cheshire Cancer Network. The Christie has developed two new satellite centre’s in the Pennine Trust and in Salford so that ambulatory care can be can be delivered more locally. The Christie expects to deliver in excess of 44,000 solid tumour chemotherapy treatments in this financial year. The majority of chemotherapy treatments are given as out-patient treatments in the Oak Road Treatment Centre at the main Christie site. A small number of treatments are given as in-patient on three of the wards at The Christie; we also provide a Haematology and Lymphoma service. For those patients between the ages of 16 and 25, chemotherapy is administered on our specialist Young Oncology Unit, tailored to the needs of this age group. The Oak Road Treatment Centre is a purpose-built unit providing care for those patients receiving outpatient chemotherapy and clinical trial treatments. It was opened in November 2010 and in addition to chemotherapy delivery houses the Phase I / II / III research facility and a private patient in-patient suite. Based on The Christie Withington site, this unit presently provides the majority of outpatient chemotherapy treatments for patients within the network. With 55 treatment chairs and 27 beds the centre is the largest chemotherapy unit in the UK and the largest single site clinical trials unit in the world. Two hundred beds are in use at the Christie. The Department of Medical Oncology beds are sited in 4 wards which are organised on a site group basis. A medical admissions unit was opened in December 2007 to improve access for clinical emergencies and provide immediate clinical care of non elective admissions. The remainder of the beds are used for chemotherapy, haematological oncology, endocrinology and surgery. There is an adult outpatient department and separate facilities for minor surgical procedures. 2 The Christie Hospital Department of Medical Oncology The Christie Hospital Department of Medical Oncology has close links with The University of Manchester. Dr. Andrew M. Wardley is Clinical Director of Medical Oncology and Chemotherapy Services. There are 22 other Consultant grade appointments in Medical Oncology. The Department of Medical Oncology is actively involved in research and routine clinical work and in joint collaborative programmes with the Department of Clinical Oncology in all aspects of oncology. Clinical Oncology and Medical Oncology Consultants work closely together in site specialised Disease Groups. The Christie Hospital Department of Medical Oncology is one of the largest departments of cancer medicine in the NHS. The major remit of the department is to develop improved methods for cancer patient management. There are both clinical and laboratory scientific research components that are closely integrated with clinical research and service work. The Department has links with Preston Oncology Centre and with the Department of Medical Oncology at Lancaster Royal Infirmary, which is included as part of the Medical Oncology higher specialist training rotation (total 17 NTN’s). The Department of Medical Oncology presently provides a service to Greater Manchester and Cheshire, and parts of Lancashire, through regular clinics (mainly weekly), staffed by its consultants (see appendix 1). The population of the Christie’s catchment area is approximately 3.2 million. A total of 13,180 new patients with cancer were seen by the Christie and associated clinics and 96958 radiotherapy fractions were delivered in 2011. The Christie provides systemic anti-cancer therapy across the Greater Manchester & Cheshire Cancer Network including at East Cheshire (Macclesfield), Mid Cheshire (Leighton), Stockport, Pennine (Oldham) and Tameside. Patients are reviewed by Christie consultants and treated by Christietrained staff on these sites. The Christie oncologists also provided systemic anticancer therapy advice to other trusts within the Greater Manchester & Cheshire Cancer Network such as Macclesfield, Wigan and Bolton. The Christie’s localising Chemotherapy Strategy 2012-15 approved by The Christie board in March 2012 sets out the relocation of treatments so that 80% of clinically appropriate treatments will be delivered at sites closer to patients’ homes. The Christie governance arrangements apply to all systemic anti-cancer therapy treatments irrespective of the service provider, ensuring all patients receive the best possible treatment, an excellent patient experience and that recruitment to clinical trials continues to increase. These ambitious targets will be met through the expansion of existing and new hospital settings and the use of community based settings. The Derek Crowther Early Phase Trial Unit and Oak Road Treatment Centre The Derek Crowther Unit is a dedicated early phase clinical trials unit and it was established on the Christie site in 2003. The subsequent development of the Clinical Experimental Pharmacology group, GCLP compliant laboratories, the Wolfson Medical Imaging Centre and the MCRC Biobank have complemented this clinical infrastructure and over the last 8 years the Derek Crowther Unit has 3 flourished, doubling its research activity to more than 10,000 patient visits annually. The unit presently supports over 100 clinical trials, recruits over 700 patients per annum to clinical research studies and collects over 18,000 biological research samples. A successful Clinical Research Infrastructure bid has allowed a major programme of infrastructure expansion for clinical trials at the Christie Hospital site and this will enable Manchester to become one of the largest centres for early phase clinical trials worldwide. This infrastructure forms part of the Oak Road Treatment Centre, a £35M development which includes enlarged facilities for clinical and translational research, service chemotherapy, pharmacy and private patients. The opening of the Oak Road Treatment Centre in November 2010 is reinforced Manchester as one of the premier sites in the world for conducting early phase clinical research. Associated Departments Clinical Oncology (Director Dr J Logue) Clinical Oncology has 25 consultants and state of the art radiotherapy equipment along with a major research centre - The Wade Centre (Director Dr John Logue). The Clinical Oncology Division provides a service to Greater Manchester and North Cheshire through clinics (mainly weekly) staffed by its consultants in every main town in the area. A good liaison exists between the divisions of Clinical Oncology and Medical Oncology. Many of the clinical protocols are run jointly between the two departments and there are excellent opportunities at Specialist Registrar level to participate in joint teaching programmes. Haematological Oncology Dr James Cavet, Dr Adrian Bloor and Dr Mike Dennis run a major transplant unit with 18 dedicated beds. Other Departments The Department of Histopathology provides a regional cancer service. The Department of Diagnostic Radiology has two whole body spiral CT scanners and two MR scanners, in addition to standard radiological and radionuclide imaging facilities. This department is currently undergoing major refurbishment, and will be re-commissioned with new and more extensive equipment next year. A PET-CT scanner was installed in early 2008. The Department of Psychological Medicine is involved in collaborative research projects concerning psychological assessment and counselling in the context of clinical trials and is responsible for staff training in aspects of psychological support. Clinical and Laboratory Scientific Research A wide range of clinical research studies are in progress. All disease groups have research teams and are major contributors to national and international trials of new treatments. These include Phase I/II and III systemic anti-cancer therapy studies, combined surgery, radiotherapy and systemic anti-cancer therapy studies and patient evaluation studies (staging procedures, psychological assessment etc). A special interest is taken in the development of new biological therapies 4 particularly anti-angiogenic therapies (lead by Professor Gordon Jayson) and gene/immunotherapies (led by Professor Robert Hawkins). Manchester has an ECMC centre led by Professor Malcolm Ranson and has close links with the Clinical Experimental Pharmacology laboratory led by Professor Caroline Dive. There is a designated Early Phase Trials Unit (director Dr. Andrew M. Wardley) where most clinical research activity occurs. Administrative facilities The post holder will have office accommodation with computer, intranet and internet access at both sites. There will be secretarial support. Ward facilities 1. General medical oncology wards – 40 inpatient beds available 2. 16 inpatient chemotherapy beds shared with Clinical Oncology. 3. The Haematology Transplant Unit (HTU), with 18 beds available for the care of adult patients with haematological malignancy and lymphoma requiring myeloablative therapy with haemopoietic rescue. 4. An 8 bedded Critical Care Unit opened in 2007. A wide range of cancers are managed in these ward facilities and practical training in all aspects of cancer medicine is provided at ST/SpR levels. Special facilities include two cell separators for leukapheresis and plasmapheresis. Outpatient facilities Routine medical oncology clinics are held daily at the Christie Trust for new patients and follow up. There are specialised cancer site related collaborative clinics and routine outpatient clinics. Several of the Consultants visit DGH’s within the Greater Manchester and Cheshire Cancer Network to undertake clinics for new and follow-up patients. We are currently reviewing our outpatient facilities, and the treatment and follow-up appointments, with a view to moving some of the activity to Cancer Units in the network. Specialist nurse facilities Teams of specialist chemotherapy and research nurses work alongside the clinicians. These nurses have special expertise and training in the administration of chemotherapy. There are specialist nurses within each disease group. Specialist nurses are also trained to insert central venous access devices, carry out bone marrow aspiration/trephine procedures, operate the cell separators for leukapheresis and provide psychological support and counselling. The Early Phase Trials Unit recently appointed 2 advanced nurse practitioners to assessment with management of trial patients. 5 3. Details of the Post It is envisaged that the post-holder would split their clinical commitments between acute oncology and gynaecological cancers and would take a leading role in the development of an acute oncology service which the post holder would provide together with established consultant colleagues within other disease site groups at Central Manchester University Hospitals. The post would be co-located at Central Manchester University Hospitals and The Christie Withington site. a). Gynaecological Medical Oncology (GMO) Team Professor Gordon Jayson, Dr Jurjees Hasan, Dr Andrew Clamp provide systemic therapy for patients diagnosed with ovarian and endometrial cancer within the Greater Manchester & Cheshire Cancer Network. Currently gynaecological oncology surgery is provided at three sites within the Network (CMFT, SMUHT, SRFT) each of which hosts a multidisciplinary team meeting. Complex pelvic surgical procedures i.e. exenterative surgery is performed at The Christie. The GMO team receives over 350 new referrals per year and provides second opinions for cases from a wide geographical area. As well as clinical work, the team plays a leading role in national and international early and late phase clinical trial development in gynaecological cancers. We were the highest recruiting centre to NCRN clinical studies in 2011-12 and also have a phase I portfolio that focuses on novel anti-angiogenic agents. This post will provide 2 clinical sessions to support the care of patients diagnosed with gynaecological cancer in the North East sector alongside Dr Clamp and Professor Jayson. It is anticipated that the post holder would attend the sector MDT (located at CMFT once a fortnight alternating with a new patient clinic on the Christie site. The second session would involve a chemotherapy/follow-up clinic. b). Acute Oncology & Cancer of Unknown Primary Central Manchester University Hospital NHS Foundation Trust are in collaboration with The Christie is planning to implement an acute oncology service. In view of the proximity of Central Manchester University Hospitals to The Christie Hospital it does not provide systemic anti-cancer therapy on site but it is a major acute hospital for Greater Manchester & Cheshire Cancer Network with considerable need for acute oncology provision. It is envisaged that this post will complement the current service which provides cancer-site specialised support through the disease groups both at The Christie and within Central Manchester University Hospital NHS Foundation Trust together with the current Hotline clinic and the development of the Acute Oncology Network Office. This post holder will lead a team of established consultants who are currently providing the clinical aspects of the acute oncology service. This post holder together with nursing support will formalise this service to provide dedicated and comprehensive acute oncology support. The post-holder will be expected to lead the cancer of unknown primary service at the centre and throughout the Greater Manchester & Cheshire Cancer Network. 6 c). Clinical Staff in Medical Oncology The medical staff establishment provides for 23 Medical Oncology Consultants, (see appendix 1) including academic consultants and 10 Specialist Registrars in Medical Oncology. There is a junior doctor team at F2 and CMT level, working jointly with Medical Oncology and Haematology, within the Division of Networked Services. d). Duties of Post The appointee will be based at The Christie Hospital and Central Manchester University Hospital, NHS Foundation Trust and will be a member of the Medical Oncology Consultant Group. The post will involve the care of gynaecological cancer patients as defined above. The post holder will be required to conduct outpatient clinics involving chemotherapy delivery, to supervise patients receiving chemotherapy and to conduct ward rounds in a manner providing optimum patient care and efficient use of the hospitals’ resources The initial allocation of sessions if the appointment is full time is expected to be: SERVICE Location Direct Clinical Care Programmed Activity Clinics at The Christie Hospital 2.5 MDT meetings 0.5 Acute Oncology 6 Including CUP activity (clinic & multi-disciplinary team meeting etc) Supporting professional 1 Activities (training, CPD, teaching, audit, clinical governance, research, appraisal and clinical management) Total 10 PAs This may be altered in response to the requirements of the medical oncology service in agreement with the Clinical Director of Medical Oncology. 7 The agreed work plan will be subject to annual review in line with Trust policy and GMC revalidation. Appraisal in accordance with GMC revalidation will occur annually. This will also include an assessment of professional development and defined goals for the future. In the event of the consultant electing to work part time a pro rata adjustment of fixed sessions would be anticipated. This will be discussed and agreed with the division. The department has evolved, over many years, a policy of mutual co-operation between the consultants. The department consultant group meets monthly to discuss joint management policies. Consultants are grouped in teams of two to six supported by junior staff .The teams accept responsibility for agreed fields of work and for cover for absence arrangements. All consultants are expected to co-operate in these arrangements and to be involved in a number of clinical areas of work. A Clinical Director, Dr A Wardley, chairs the department. The Medical Oncology Department works with the departments of clinical oncology, young oncology and palliative care as part of the Network Services Division, with Jason Dawson as Deputy Chief Operating Officer. All consultants in the department share in an on-call rota that involves a commitment to a full week in every four months. This covers the specialist registrar who is second on-call. A Ward round every morning is expected so that patients are reviewed within 24-hours of admission by a consultant. Consultants provide advice on their area of expertise to all affiliated hospitals in the network as required within the disease group that they work in and to provide emergency advice as required to hospitals in the Greater Manchester & Cheshire Cancer Network when on call. The appointee will have office accommodation and access to a secretarial service. e). Administration The appointee will be a member of the Department of Medical Oncology consultant group. The appointee will also be a member of The Christie medical liaison and advisory group. The clinical director within the consultant group negotiates administrative duties within the Medical Oncology Department and consultants are expected to accept responsibility for at least one area. This responsibility is regularly reviewed and can be altered following consultation and agreement with the Director and colleagues. The present Executive Directors of the Trust are: Caroline Shaw Ian Moston Dr Chris Harrison Jackie Bird Roger Spencer Chief Executive Executive Director of Finance & Performance Medical Director Executive Director of Nursing & Governance Chief Operating Officer 8 The Trust board is chaired by Lord K Bradley. f). Teaching The Christie School of Oncology The Christie Education Directorate provides undergraduate and postgraduate education and training in oncology and palliative care to a wide spectrum of professionals involved in the care of cancer patients. This will be in partnership with the University of Manchester. The successful applicant would be expected to play an important role in the activities of the Christie School of Oncology. The department of medical oncology participates in the clinical undergraduate teaching programme of the University of Manchester and students visit the hospital for seminar, outpatients and bedside teaching at different stages in their training. There are dedicated courses designed for postgraduate students studying for the Part I and II examinations of the Fellowship of the Royal College of Radiologists. Consultants are expected to participate in the specialist registrar and F2 teaching programme. Post-graduate training is co-ordinated by the Medical Oncology specialty training group. The Training Programme Director in Medical Oncology is Dr Was Mansoor. Undergraduate training is coordinated by Professor R A Cowan, Director of Education. The hospital has a Medical Library staffed by professional librarians offering a range of services including a modern journal collection, extensive book library and on line search facilities. Education • Promote excellence in learning and teaching and directly teach and mentor undergraduate medical students for the university. • Play a full role in postgraduate training of doctors and other professionals allied to medicine • Provide academic leadership and innovation in learning and teaching • Contribute to leadership and coordination of quality assurance and enhancement activities and preparations for review by external agencies. g). Particulars of Contract Any consultant who is unable for personal reasons to work full-time will be eligible to be considered for the post. The job content will be discussed on a personal basis and agreed with the Trust. h). Job Planning All job plans will be reviewed annually. The annual review will examine all aspects of the job plan and should be carried out jointly by the Clinical Director and the post holder. 9 THE CHRISTIE NHS FOUNDATION TRUST TERMS AND CONDITIONS OF EMPLOYMENT The terms and conditions of the New Consultant Contract are applicable Salary: Will be on the New Consultant Contract pay scale Annual Leave: 0 - 7 years seniority six weeks and 2 days per annum (pro rata for part time employees) 7+ years seniority six weeks and 4 days per annum (pro rata for part time employees) Bank Holiday: 8 public holidays Resident: The successful candidate will be required to live within a reasonable travelling distance of the Trust. Arrangements to visit the hospital may be made direct with the: Department of Medical Oncology The Christie NHS Foundation Trust Wilmslow Road Withington Manchester M20 4BX Telephone number: 0161 446 8457 Clinical Director: Dr A Wardley PA: [email protected] Tel: 0161 446 3746 Gynaecological Malignancy enquiries Prof Gordon Jayson PA: Lisa Watmough Tel: 0161 446 3606 10 Terms and Conditions of Service PAY The salary details for this post are based on the New Consultant Contract Terms and Conditions. You will have an honorary contract with the Christie Trust subject to appropriate verification of qualifications, CRB checks and so on. This in turn means the following conditions apply. CONFIDENTIALITY You must maintain the confidentiality of information about patients, staff and other health service business. HEALTH AND SAFETY Employees must be aware of the responsibilities placed on them under the Health & Safety at Work Act (1974), to ensure that the agreed safety procedures are carried out to maintain a safe environment for employees. RISK MANAGEMENT All staff have a responsibility to report all clinical and non-clinical accidents or incidents promptly and when requested to co-operate with any investigation undertaken. EQUAL OPPORTUNITIES The Trust has adopted an equal opportunities policy and it is the duty of every employee to comply with the detail and spirit of the policy. CONFLICT OF INTEREST The Trust is responsible for the service for the patients in its care meets the highest standards. Equally, it is responsible for ensuring that staff do not abuse their official position to gain or to benefit their family or friends. The Trust’s standing orders require any officer to declare any interest, direct or indirect with contracts involving the Trust. Staff are not allowed to further their private interest in the course of their NHS duties. NO SMOKING The Trust operates a no smoking policy. MEDICAL EXAMINATION All appointments with the Christie NHS Foundation Trust are subject to pre-employment health screening. 11 APPENDIX 1 MEDICAL ONCOLOGY CONSULTANT STAFF Clinical Staff There are 23 consultants in the department of Medical Oncology: Dr Anne Armstrong Dr Fiona Blackhall Dr Mike Braun Dr Andrew Clamp Dr. Rafaelle Colifano Dr. Emma Dean Dr Jurjees Hassan Professor Robert Hawkins Dr Richard Hubner Professor Gordon Jayson Dr Michael Leahy Dr Kim Linton Dr Paul Lorigan Dr Was Mansoor Dr Saifee Mullamitha Professor John Radford Professor Malcolm Ranson Dr Yvonne Summers Dr Paul Taylor Dr Fiona Thistlethwaite Professor Juan Valle Dr Andrew Wardley, Dr Greg Wilson Breast Cancer – linking with Crewe Lung Cancer Colorectal – linking with Crewe College Tutor, Gynaecologic Cancer Lung- with University Hospital of South Manchester NSFT Phase I and Melanoma Colorectal and Ovarian Renal, Gastric and Immunotherapy Phase I Trials Upper GI and hepatobiliary Ovarian Cancer and Anti-Angiogenesis Phase I Trials Sarcoma and Teratoma, Clinical Director Young Oncology Unit Lymphoma Melanoma Oesophago-Gastric/NET, TPD Colorectal Cancer – link with Pennine Trust Lymphoma, Clinical director R&D Clinical Pharmacology, Phase I trials Lung- with University Hospital of South Manchester NHSFT Lung-with University Hospital of South Manchester NHSFT Upper GI & Renal Hepatobiliary and Neuroendocrine Clinical Director of Medical Oncology and Chemotherapy Services Clinical Director Early Phase Trials Unit, Breast Cancer Consultant Breast and Colorectal Cancer There are at present ten Specialist Registrars, seven SHO level posts and 7 F2 doctors. Eight Clinical Research Fellows also participate in clinical activities, in addition to their laboratory research. 12 APPENDIX 2 PERSON SPECIFICATION - CONSULTANT IN MEDICAL ONCOLOGY ATTAINMENTS Education ESSENTIAL DESIRABLE MB.ChB. or equivalent Higher Degree MD. Ph.D MRCP or equivalent Training Certificate of completed specialist training or equivalent (or within 6 months of CCT by interview) Postgraduate qualification in Medical Education Management experience Research experience Job experience GENERAL INTELLIGENCE SPECIAL APTITUDES INTERESTS DISPOSITION Acceptability Appropriate experience in Gynaecological Malignancy oncology Demonstrates knowledge, logic and efficiency Integrity, management and communication skills including teaching Developments in oncology practice Knowledge of continuing NHS and Royal College Reforms. Is a team player prepared to adapt to changing circumstances. Leadership Dynamic, decision-making motivator. Self-reliance Confident in ability, but knowing own limitations. Motivation Hardworking, enthusiastic achiever. Good attendance record. Patient friendly. Professional demeanour Must be resilient and well organised 13 Person Specification REQUIREMENTS ESSENTIAL DESIRABLE Qualifications MB.ChB. or equivalent MRCP or equivalent Certificate of completed specialist training or equivalent (or within 6 months of CCT by interview) Training & Experience Evidence of wide experience and training in general and oncological medicine and of research Demonstrated interest and experience in teaching/education Attendance at “Teaching for Teachers” or equivalent Experience of teaching undergraduate/postgraduate trainees Evidence of involvement in hospital management Has attended a management course Academic / Research Achievements Clinical and translational research experience. Evidence of ability to provide academic leadership Potential to progress to having an international research profile Ability to apply for and be successful in being awarded peer reviewed grant income. Recent articles in peer reviewed publications. The ability to initiate, design and supervise clinical research. Evidence of ongoing national/international research collaboration Recipient of research award or prize Ability to communicate and collaborate effectively with colleagues in other disciplines. Ability to manage research projects Ability to supervise postgraduate research students and assistants Personal Skills Demonstrable interpersonal skills. Evidence of excellent written and oral communication skills. Flexible approach to work. The ability to work as part of a multi-disciplinary team. Good time management skills, with the ability to prioritise and handle competing demands. Personal Circumstances Reliable work record. Good health record. Living within reasonable travelling distance of The Christie 14 APPENDIX 3 B) University of Manchester The University of Manchester The University became the largest single site University in the UK in 2005 with the merger of the Victoria University of Manchester and the University of Manchester Institute of Science and Technology (UMIST). Currently approximately 40th in the world rankings, it has an ambitious programme of development to become one of the top 25 universities in the world by 2015. Development is occurring University wide and cancer is one of two areas selected for rapid development. It has significant existing activities in cancer research within the Faculties of Medical and Human Sciences and Life Sciences. The Faculty of Medical and Human Sciences The Faculty is large and comprehensive, with all the important healthcare disciplines represented in both research and teaching. Today, the Faculty has an annual research income of £51M, almost a third of the University’s total research income. There are 7,600 undergraduate students and 1,600 postgraduates on award-bearing courses. More students graduate each year from the School of Medicine than from any other medical school in the UK. The Faculty’s goal for 2015 is to be a world leader in the translation of key elements of biomedical research to patient care, working in collaboration with the NHS and industrial partners. The Manchester Academic Health Science Centre (MAHSC) is a partnership between six NHS organisations in Greater Manchester and The University of Manchester. It is based on a federal model and is the first AHSC in the UK to cover the full spectrum of care (http://www.mahsc.ac.uk). The School Cancer and Enabling Sciences in the Faculty of Medical and Human Sciences The focus for academic cancer medicine in the university is the Cancer and Enabling Sciences Research School and has over 60 academic staff including 36 academic clinicians. The jobholder will be based in the School. The total number of staff in the Cancer Research Group is 140. Interests span from biomarker studies using clinical proteomics and microarray analyses to advanced imaging within the Wolfson Molecular Imaging Centre on the Christie site, and elsewhere (see http://www.wmic.manchester.ac.uk/, http://www.bii.manchester.ac.uk/) . The School has a first rate publication record in high impact medicine and cancer journals. The development of close relations between the Christie NHS Foundation Trust underpins future plans for research endeavours within the School. The School has a research income of approximately £12m a year from industry, research councils and charities, a 23% increase on the previous year (2008/9). The present management team is: Professor Steve Williams Head of School and Head of the Imaging, Genomics & Proteomics Research Group Professor Vaskar Saha Head, Cancer Studies Research Group 15 The Faculty is currently undergoing a restructuring under the leadership of the Faculty Dean, Professor Ian Jacobs. Cancer Studies will be refigured as a new Faculty Institute, which will actively interact with researchers into cancer in other professional disciplines such as Pharmacy and Nursing as well as with clinical colleagues. The Paterson Institute for Cancer Research The Institute is a leading cancer research institute funded by CR-UK. Research spans the whole spectrum of cancer research, from programmes investigating the molecular and cellular basis of cancer, to those focused on translational research and the development of novel therapeutic approaches and experimental pharmacology. The Institute works in close collaboration with The Christie NHS Foundation Trust and the School. Manchester Cancer Research Centre The Manchester Cancer Research Centre (MCRC) was established in 2006 to bring together the expertise, ambition and resources of partner organisations that already have formidable individual reputations in the fields of cancer treatment and clinical research. The partner organisations are The University of Manchester (including the Paterson Institute for Cancer Research), The Christie NHS Foundation Trust and Cancer Research UK. The MCRC has outstanding facilities where researchers and clinicians can work closely together. The joint aim is to gain a greater understanding of the fundamental basis of how cancer develops and apply that knowledge to develop new diagnostic tests, new treatments and better ways to predict outcomes in order to optimise treatment options and care for cancer patients. Recently new first class translational research facilities have been opened to support current activities and develop into new areas such as molecular pathology. New laboratories which meet Good Clinical Laboratory Practice standards have been completed and commissioned and these improve our ability to assess clinical samples from early phase trial patients under the strict regulations which are now required. These activities are supported with major grants from the Experimental Cancer Medicines Centre initiative and the Clinical Research Initiative, the latter allowing us to increase the capacity for early phase clinical trials to world leading levels. In addition, the regional tissue Biobank provides a valuable and accessible resource to underpin a diversity of cancer research programmes. Manchester has now been awarded Centre status by Cancer Research UK, underpinning research and training on the Christie site and elsewhere 16 g) Research The Christie NHS Foundation Trust is committed to cancer research and recruits over 1900 patients per year to clinical trials. The Division of Clinical Research is led by Professor John Radford, the Trust R&D Director. The largest Early Phase Trials Unit in Europe was opened in November 2010. The Early Phase Trials Unit Director is Dr. Andrew M. Wardley, was recently awarded a £4.5 Million grant from NIHR for clinical research infrastructure. Future projects include the development of a Molecular Diagnostics Unit, which has already commenced, and £3.5m for the development of a Gene Therapy Centre. These, along with other developments, will further enhance the research standing of the Trust. Attached to The Christie is the University of Manchester Paterson Institute, an extensive complex of laboratories supported by the Cancer Research UK (Director - Professor Richard Marais). The Institute is dedicated to fundamental and clinically orientated translational cancer research in many fields including radiobiology, haematology, molecular biology, immunology, tumour chemotherapy and cytogenetics. A translational research facility is being built. There are opportunities for clinical research in developmental RT, chemo-radiotherapy and biological therapies. 17